Crandall Ryan 4

What Happened

• Ryan Crandall, Chief Commercial Officer of Marimed Inc. (MRMD), reported RSUs converting to common stock on March 28, 2026. The filing shows an acquisition (conversion) of 6,047 shares at $0.00 (code M), and 2,096 shares withheld to satisfy tax obligations at $0.08 per share (code F) for a reported withholding value of $159. Net shares delivered to Crandall were 3,951 (6,047 acquired minus 2,096 withheld). The filing also records a 6,047-share derivative disposition (code M), reflecting conversion/settlement of the RSU award.

Key Details

• Transaction date: March 28, 2026 (reported on Form 4 filed March 30, 2026 — timely).
• Reported entries: M — 6,047 shares acquired at $0.00; F — 2,096 shares disposed/withheld at $0.08 (reported $159); M — 6,047 derivative disposition at $0.00.
• Net new shares to insider: 3,951 shares (6,047 acquired less 2,096 withheld).
• Shares owned after transaction: Not specified in the excerpt of the filing.
• Footnotes: F1 — RSUs convert 1-for-1 to common stock; F2 — withheld shares used to satisfy tax withholding; F3 — this grant was originally made March 28, 2024, with remaining vesting scheduled for 9/28/2026 and 3/28/2027.
• Transaction codes: M = exercise/conversion of a derivative (RSU conversion); F = shares withheld for tax liability.

Context

• This transaction reflects a routine RSU vesting and settlement rather than an open-market purchase or sale. The withholding of shares to cover taxes is common and does not necessarily indicate a trading decision or change in sentiment. For RSU settlements like this, the derivative (RSU) is converted to common stock and a portion may be retained by the issuer to meet tax obligations.